8 July 2016|

In a paper recently published in the journal Blood, Dr. David Andrews’ group used high-content screening to test 320 kinase inhibitors and identify ones that, when given in combination with venetoclax, can overcome resistance to the drug. Venetoclax inhibits the anti-apoptotic protein Bcl-2 and received breakthrough status from the U.S. Food and Drug Administration this year. It is available in the U.S. to treat patients with chronic lymphocytic […]